Compare ASMB & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | EU |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 464.5M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | EU |
|---|---|---|
| Price | $26.22 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.40 | $4.00 |
| AVG Volume (30 Days) | 98.7K | ★ 3.5M |
| Earning Date | 03-19-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,191,000.00 | ★ $44,142,000.00 |
| Revenue This Year | $33.33 | $17.41 |
| Revenue Next Year | N/A | $95.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $1.01 |
| 52 Week High | $39.71 | $4.19 |
| Indicator | ASMB | EU |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 41.65 |
| Support Level | $25.47 | $2.60 |
| Resistance Level | $27.50 | $2.90 |
| Average True Range (ATR) | 1.75 | 0.24 |
| MACD | 0.23 | -0.07 |
| Stochastic Oscillator | 35.04 | 4.17 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.